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Abstract: 
Computational genome analysis enables systematic identification of potential immunogenic proteins within a pathogen. Immunogenicity is a system 
property that arises through the interaction of host and pathogen as mediated through the medium of a immunogenic protein. The overt dissimilarity of 
pathogenic proteins when compared to the host proteome is conjectured by some to be the determining principal of immunogenicity. Previously, we 
explored this idea in the context of Bacterial, Viral, and Fungal antigen. In this paper, we broaden and extend our analysis to include complex antigens of 
eukaryotic origin, arising from tumours and from parasite pathogens. For both types of antigen, known antigenic and non-antigenic protein sequences 
were compared to human and mouse proteomes. In contrast to our previous results, both visual inspection and statistical evaluation indicate a much wider 
range of homologues and a significant level of discrimination; but, as before, we could not determine a viable threshold capable of properly separating 
non-antigen from antigen. In concert with our previous work, we conclude that global proteome dissimilarity is not a useful metric for immunogenicity for 
presently available antigens arising from Bacteria, viruses, fungi, parasites, and tumours. While we see some signal for certain antigen types, using 
dissimilarity is not a useful approach to identifying antigenic molecules within pathogen genomes. 
 
 
 
 
Background: 
Vaccines induce provoke protective immunity and come in both “living” 
and “non-living” varieties. Living vaccines are usually attenuated or 
weakened pathogenic microbes which retain aspects of natural infection 
including the ability to revert to a pernicious form. Non-living vaccines are 
either chemically or heat treated whole pathogens or pathogen 
components. Subunit vaccines comprise protein components isolated from 
pathogenic micro-organisms and have several advantages: they have 
longer shelf-lives, are more stable, and cannot regain pathogenic status. 
However, their identification can be arduous requiring the expense of 
much time and resource.  
 
Tumour immunotherapy refers to using the host immune system to battle 
cancer. Strictly, a tumour is a solid lesion or neoplastic growth resulting 
from unregulated cell division, and may be benign, pre-malignant, or 
malignant; we use the term synonymously with cancer, and specifically 
here as a pseudonym for human tumour antigens extracted from the 
SEREX database. Tumour vaccines contain a specific protein derived from 
a tumour able to stimulate a protective immune response. Tumour vaccines 
are therapeutic rather than prophylactic in nature, and are typically injected 
subcutaneously or directly into cancerous tissue. They are a nascent form 
of personalised medicine, with different vaccines targeting different 
cancers, with the potential to identify antigens directly from the patient. 
 
Diseases of parasite and protozoan origin cause significant mortality and 
morbidity: over 3.5 billion people currently suffer parasitic infection, 
primarily in tropical and subtropical countries, particularly pastoral regions 
of Asia, Latin America, and Africa; incidence in industrialized countries is 
relatively low. Parasites typically invade the body via mucosal surfaces. 
Buccal parasites, for example, after ingestion will either remain in the 
intestine or escape via the intestinal wall, invading other organs; while 
some will bore through the skin or enter via insect bites. The life-cycles of 
many parasites, particularly single-celled parasites, are complex with many 
stages involving eggs and larval forms yet usually reproduce within the 
host. This makes developing vaccines extremely problematic, and 
currently there are no licensed vaccines available targeting parasitic 
diseases.  
 
Genomics is fashioning a new epoch of knowledge-led vaccine design and 
discovery. Known as reverse vaccinology, it combines advanced molecular 
biology technology with advanced in silico analysis of pathogen genomes, 
enabling the systematic identification of potential antigens within a 
pathogen. Key to this endeavour is the bioinformatics protocols used to 
detect antigens, such as those which predict sub-cellular location as the 
main determinant associated with antigens. As proposed by Kundac et al. 
[1], another persuasive concept is the idea of dissimilarity of antigens 
versus non-antigens at the sequence level. In this paper, we extend our 
previous analysis [2, 3] beyond bacteria, viruses, and fungi, to explore 
parasite and tumour antigens. 
 
Methodology: 
Datasets of known antigens obtained previously from the literature were 
analysed [2, 3, 4, 5]. Non-antigens were randomly selected from Swiss-
Prot so that they mirrored the species distribution within the antigen sets 
[2, 3]. Parasite and Tumour antigens used here are listed below in Figure 
1. Additionally, genomes corresponding to Human, Mouse, and Parasite 
were downloaded from FTP sites at National Center for Biotechnology 
Information (NCBI) [http://www.ncbi.nlm.nih.gov/], European 
Bioinformatics Institute (EBI) [http://www.ebi.ac.uk/], and Ensembl 
[http://www.ensembl.org/], and tumour sequences from the SEREX 
datasets available from the Cancer Immunome Database [http://ludwig-
sun5.unil.ch/CancerImmunomeDB/]. Tumour non-antigens were collected 
at random by selecting human proteins from Swiss-Prot. All the peptide 
sequences obtained were in FASTA format. Bioinformation  Volume 5 
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As before [2, 3], antigen datasets, non-antigen datasets and parasite 
genomes were compared to the Human and Mouse Genome, and analysed 
with a local, standalone version of BLAST [6], which afforded full 
management of E-value cut-offs. E-value thresholds were raised from 10 to 
6000 to identify best matches even when these lacked statistical 
significance. We also analysed (log10
E-value)+1 values obtained from 
BLAST. By using the statistical package Minitab, Release 14.1, we 
compared antigen and non-antigen sets, as random samples of two larger, 
independent populations, utilising a Mann–Whitney test. 
 
Discussion: 
Previously, we have examined the difference between sets of antigens and 
non-antigens for Bacterial, fungal, and species, and found no clear 
separation of the two, concluding that proteome dissimilarity does not 
provide a means of sifting out potential antigens from a newly sequenced 
pathogen genome. Here we have expanded our analysis, focusing on 
parasite and tumour antigens. 
 
Compared to our previous sequence similarity analyses [2, 3], parasite 
non-antigens evinced more noticeable dissimilarity to the human genome 
than did parasite antigens, suggesting a clearer separation than before. See 
Figure 2. However, there were seven antigenic proteins that demonstrated 
high similarity to the human genome compared to one equivalently similar 
non-antigen. We also evaluated the genomes of four different parasite 
species – Cryptosporidium parvum, Distyostelium discoideum, Leishmania 
infantum  and Trypanosoma brucei – as a background reference, or a 
“control” as some would put it, for this comparison of antigens and non-
antigens, comparing them to both human and mouse genomes. The 
distribution of matches between parasite and human genomes indicates that 
most proteins lie inside the range characterising the antigen proteins. While 
a signal is clearer here than before [2, 3], the distribution is inverted 
compared to our expectation: a discernible proportion of the antigens were 
more similar, not less, than are the non-antigens. Thus for these proteins, 
antigenicity is encoded in a subtle and cryptic manner, not apparent simply 
from sequence comparison. It is possible, but likely, that using some form 
of similarity filter - rather than a dissimilarity filter - may provide a 
threshold able to indicate the potential antigenicity of parasite proteins. 
 
We observed that the distributions of tumour antigen matches to the human 
and mouse genomes spread across a wide E-value range scale, much wider 
than seen previously [2,3]. Figure 3 illustrates the analysis of tumour 
antigens, non-antigens, and reference genomes relative to the human 
genome. The distributions characterizing antigens and non-antigens were 
similar, yet antigens were by visual inspection proportionally more similar 
to the human genome relative to non-antigens. This observation is again 
inverted compared to our expectations, as was the case for parasites. This 
distribution may in part result from the presence of both antigens and non-
antigens in the host. Thus identifying a threshold able to separate tumour 
antigens from non-antigens would again prove difficult.  
 
As well as visual inspection of the distributions of antigens and non-
antigens for tumour and parasite, we also undertook a statistical 
comparison using the Mann–Whitney Test. At a 95% confidence level, the 
test gave a value of 0.000 for Parasite and 0.001 for Tumour. All previous 
assessments accepted the null hypothesis. Since these values are less than 
0.05, this is indicative of a statistically significant discrepancy between the 
two antigen-versus-non-antigen distributions from both tumours and 
parasites. While the apparent significance for parasite and tumour was 
marked, it was somewhat at odds with the visual inspection of the 
histograms of similarity values. Although there may be a statistically 
significant difference in both paired distributions, there is again no useable 
cut-off capable of distinguishing antigen from non-antigen. 
 
 
Figure 1:  Protein sequences compiled and annotated as antigens of Parasite and Tumour origin. Parasite sequences are denoted by their Swiss-
Prot/TrEMBL codes. Tumour sequences are denoted by their SELEX codes.  Bioinformation  Volume 5 
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Figure 2: A sequence similarity comparison with the E-value as 6000 and BLOSUM 62 matrix, between the Antigen, Non-antigen and Cryptosporidium 
parvum genome sequences. Two separate scales were used as the number of matches to the Human Genome varied from the antigen and non-antigen 
datasets to the genome. The blue line with the star marker signifies the genome is plotted on the right hand axis (Y axis). 
 
 
Figure 3: A sequence similarity comparison between Tumour antigens and the whole human proteome. E-value set at 6000 and BLOSUM 62 matrix, 
between tumour Antigen and Non-antigen. All self-matching identities were excluded from the results. A background control at the genome level was not 
conducted.  Bioinformation  Volume 5 
open access 
www.bioinformation.net  Issue 1  Hypothesis
 
    
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 5(1): 39-42 (2010)    © 2010 Biomedical Informatics
 
 
42
Conclusion: 
Antigens are the basis of subunit vaccines, and their identification by 
computationally-driven reverse vaccinology is vital, particularly in the era 
of emergent zoonotic infections and recrudescent disease, since many 
recently discovered pathogens cannot be cultivated, thus precluding the 
facile experimental identification of their immunogenic antigens. To this 
endeavour, immunoinformatics searches continually for robust and 
celeritous approaches to antigen prediction. One such is based on global 
dissimilarity searching, as suggested by Kanduc et al. [1].  
 
When compared to our previous analyses [2, 3], both tumour and parasite 
distributions had a clearer and more discernible signal than before. 
However, both were inverted relative to our expectations, with antigens 
being more similar to the human genome than non-antigens. We felt this 
was counter-intuitive, but there may be evolutionary arguments consistent 
with this observation. Being so close to mammalian hosts, parasites may 
need to have evolved more complexity at the functional, and thus sequence 
and structural, levels, in order to allow their own primitive immune 
systems, to recognise and protect themselves from self-inflicted damage. 
Of course, such may be wholly specious arguments, and the true source of 
the apparent differences manifest as signal, may come from a statistical 
quirk or an observed sampling bias.  
 
The present work is not definitive, and there is much further work that 
could be done, though radically different results seem unlikely. We 
envisage repeating our study as more antigens become available [7]; 
looking perhaps at functionally or immunologically congeneric subsets 
within the overall data; using more sensitive and sophisticated similarity 
assessment operating at both the global and local levels; and combining 
this approach with other methodology in a more extensive, rigorous, and 
comprehensive analysis. 
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